Knowing your options: Lenders must run multiple scenarios to close the deal
Regardless of where rates are headed, lenders must quote deals in multiple ways to meet the client’s needs.
The economy is heading into 2025 on solid footing, but changes in Washington and geopolitical risks abroad raise questions
Heading into 2025, a variety of factors could reinforce or derail positive sentiment among business leaders, including shifts in political power, decreasing interest rates, geopolitical turmoil and others.
Key Perspectives - Economic Outlook
Each quarter, KeyBank’s Director of Applied Economics and Analytics Ben Demko breaks down recent data focused on macroeconomic, industry, and market risks for stress testing, loss estimation, asset management, resource allocation, and profit planning. The results are used in our Economic Outlook newsletter.
Inflation in focus: How middle market leaders are responding
Inflation is pushing business leaders to make tough decisions about how to move forward. Rising costs and shrinking profit margins are creating uncertainty, while the need for increased productivity through technology and process improvements is more crucial than ever.
What’s happening to Medicare Advantage? A panel discussion
Medicare Advantage is in the news. A once highly attractive, fast-growing market has whipsawed dramatically, leaving stakeholders uncertain about immediate prospects, longer-term consequences, and the future of the program. To discuss these developments, we enlisted leaders from Cain Brothers’ managed care team.
The Future of B2B Embedded Payments
If you’ve ever booked a ride with Uber or shopped on Amazon, you’ve used embedded payments. Rather than manually entering credit card information or leaving the merchant’s website or app to complete a transaction, users pay with embedded payments by clicking a button, like Apple Pay or Google Pay.
The potential of large-molecule drugs and how technology investments can help tap it
The pharmaceutical market is broken down into two categories: small-molecule drugs, which are derived from chemicals created in a lab, and large-molecule drugs, which are extracted from living organisms.
Health systems, private equity, and the government: It’s complicated
Is private equity the cause of or the solution to all of healthcare’s problems? Wyatt Ritchie, Group Head and Managing Director of Cain Brothers, a division of KeyBanc Capital Markets, joins Dave Johnson, CEO of 4sight Health, for a conversation about private equity’s role in healthcare transformation.
The Great Grid Rush: A frantic scramble for power
At the intersection of business growth, climate change and unprecedented power demand, it’s imperative to revolutionize our power infrastructure. But what does that look like? Here we explore the current state of load growth, critical resources to meet the demand, and challenges that must be addressed before it’s too late.
Optimistic middle market leaders are setting their sights on growth
Despite market performance, optimism has increased for middle market business leaders looking to the second half of 2024. According to KeyBank’s latest Middle Market Sentiment survey of 700 owners and executives of businesses with $10 million to $1 billion in annual revenue, respondents are displaying a renewed confidence in their companies’ financial performance — with optimism jumping to its highest level in years. In the survey, 78% of middle market leaders characterized the outlook for their companies over the next 12 months as excellent or very good.
Tax-exempt bonds offer a unique opportunity to secure low-cost debt
Learn how sophisticated affordable housing debt providers are finding creative solutions to meet borrower needs.
Surprising resilience: Multifamily investment remains the industry darling
Interest rate volatility and widespread economic uncertainty have curtailed multifamily investment and financing activity in the past two years. Learn more about the asset class’s resiliency and how the strong fundamentals have resisted economic trends.
